ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
August 25, 2021Sutro Biopharma today announced that the U.S.FDA has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC). -
Sutro Biopharma Announces Interim Data on STRO-002 Study for Ovarian Cancer
December 24, 2020Sutro Biopharma has provided a clinical update from the company's ongoing dose-escalation Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer.
Pharma Sources Insight January 2025
